CV Sciences (CVSI) Common Equity (2010 - 2026)

CV Sciences has disclosed Common Equity across 17 years of filings, most recently posting $1.6 million for Q2 2026.

• In Q2 2026, Common Equity fell 12.87% year-over-year to $1.6 million; the TTM figure through Jun 2026 stood at $1.6 million (down 12.87% YoY), while the FY2025 annual figure was $1.5 million, down 18.22% from the prior year.
• Common Equity came in at $1.6 million for Q2 2026 at CV Sciences, up from $1.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $5.0 million in Q1 2023 to a low of -$777000.0 in Q4 2022.
• Average Common Equity over 5 years is $2.2 million, with a median of $1.9 million recorded in 2022.
• Year-over-year, Common Equity slumped 121.93% in 2022 and jumped 473.62% in 2023.
• Over 5 years, Common Equity stood at -$777000.0 in 2022, then jumped by 473.62% to $2.9 million in 2023, then sank by 38.17% to $1.8 million in 2024, then decreased by 18.22% to $1.5 million in 2025, then gained by 7.02% to $1.6 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $1.6 million in Q2 2026, $1.5 million in Q1 2026, and $1.5 million in Q4 2025.